Online inquiry

IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5057MR)

This product GTTS-WQ5057MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Hidradenitis suppurativa (HS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5057MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ452MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ13597MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ7269MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ7304MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ12893MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ2062MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ5517MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ2290MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN1007
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW